Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Notes Payables for 5 consecutive years, with $3.7 million as the latest value for Q1 2018.

  • For Q1 2018, Notes Payables changed N/A year-over-year to $3.7 million; the TTM value through Mar 2018 reached $3.7 million, changed N/A, while the annual FY2017 figure was $3.5 million, 5.55% up from the prior year.
  • Notes Payables hit $3.7 million in Q1 2018 for Viking Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.7 million in Q1 2018 and bottomed at $304274.0 in Q4 2014.
  • Average Notes Payables over 5 years is $2.4 million, with a median of $2.5 million recorded in 2015.
  • Year-over-year, Notes Payables soared 721.63% in 2015 and then rose 5.55% in 2017.
  • Viking Therapeutics' Notes Payables stood at $304274.0 in 2014, then skyrocketed by 721.63% to $2.5 million in 2015, then surged by 30.78% to $3.3 million in 2016, then rose by 5.55% to $3.5 million in 2017, then rose by 7.82% to $3.7 million in 2018.
  • According to Business Quant data, Notes Payables over the past three periods came in at $3.7 million, $3.5 million, and $3.2 million for Q1 2018, Q4 2017, and Q3 2017 respectively.